NCCN Guidelines for HR+ HER2 Metastatic Breast Cancer

Debu Tripathy, MD, and Hatem Soliman, MD, reflect on the NCCN guideline criteria and patient factors that play into decision making for frontline therapy in hormone receptor–positive metastatic breast cancer.

• Categoria